Boston Scientific Corporation (BSX)

US — Healthcare Sector
Peers: SYK  MDT  DHR  GILD  PFE  AMGN  ABT  SNY  HCA  MCK 

Automate Your Wheel Strategy on BSX

With Tiblio's Option Bot, you can configure your own wheel strategy including BSX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

News

BSX Stockholder Alert: Shareholder Rights Law Firm Robbins LLP Reminds Investors of the Class Action Lawsuit Against Boston Scientific Corporation
BSX
Published: March 06, 2026 by: PRNewsWire
Sentiment: Neutral

SAN DIEGO, March 6, 2026 /PRNewswire/ -- Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Boston Scientific Corporation (NYSE: BSX) common stock between July 23, 2025 and February 3, 2026. Boston Scientific is a global company that develops, manufactures, and markets medical devices used across various specialties.

Read More
image for news BSX Stockholder Alert: Shareholder Rights Law Firm Robbins LLP Reminds Investors of the Class Action Lawsuit Against Boston Scientific Corporation
BOSTON SCIENTIFIC CORPORATION (BSX) INVESTOR ALERT Investors With Large Losses in Boston Scientific Corporation Should Contact Bernstein Liebhard LLP To Discuss Their Rights
BSX
Published: March 06, 2026 by: GlobeNewsWire
Sentiment: Neutral

Boston Scientific Shareholders Between July 23, 2025 and February 3, 2026 - Contact Bernstein Liebhard For More Information Regarding Shareholder Lawsuit

Read More
image for news BOSTON SCIENTIFIC CORPORATION (BSX) INVESTOR ALERT Investors With Large Losses in Boston Scientific Corporation Should Contact Bernstein Liebhard LLP To Discuss Their Rights
BSX DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Boston Scientific (BSX) Investors of Securities Class Action Deadline on May 4, 2026
BSX
Published: March 06, 2026 by: GlobeNewsWire
Sentiment: Neutral

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Boston Scientific To Contact Him Directly To Discuss Their Options

Read More
image for news BSX DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Boston Scientific (BSX) Investors of Securities Class Action Deadline on May 4, 2026
Why Is Boston Scientific (BSX) Down 6% Since Last Earnings Report?
BSX
Published: March 06, 2026 by: Zacks Investment Research
Sentiment: Negative

Boston Scientific (BSX) reported earnings 30 days ago. What's next for the stock?

Read More
image for news Why Is Boston Scientific (BSX) Down 6% Since Last Earnings Report?
Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Boston Scientific Corporation (BSX)
BSX
Published: March 06, 2026 by: GlobeNewsWire
Sentiment: Neutral

NEW YORK, March 06, 2026 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a securities class action lawsuit has been filed in the United States District Court for the District of Massachusetts on behalf of all persons or entities who purchased or otherwise acquired Boston Scientific Corporation (“Boston Scientific” or the “Company”) (NYSE: BSX) securities between July 23, 2025 to February 3, 2026, inclusive (the “Class Period”).

Read More
image for news Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Boston Scientific Corporation (BSX)
Here's Why Boston Scientific (BSX) is a Strong Growth Stock
BSX
Published: March 06, 2026 by: Zacks Investment Research
Sentiment: Positive

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Read More
image for news Here's Why Boston Scientific (BSX) is a Strong Growth Stock
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Boston Scientific Corporation - BSX
BSX
Published: March 03, 2026 by: GlobeNewsWire
Sentiment: Neutral

NEW YORK, March 03, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Boston Scientific Corporation (“Boston Scientific” or the “Company”) (NYSE: BSX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.

Read More
image for news INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Boston Scientific Corporation - BSX
Boston Scientific Corporation (BSX) Presents at TD Cowen 46th Annual Health Care Conference Transcript
BSX
Published: March 03, 2026 by: Seeking Alpha
Sentiment: Neutral

Boston Scientific Corporation (BSX) Presents at TD Cowen 46th Annual Health Care Conference Transcript

Read More
image for news Boston Scientific Corporation (BSX) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Boston Scientific Corporation (BSX) Is a Trending Stock: Facts to Know Before Betting on It
BSX
Published: February 26, 2026 by: Zacks Investment Research
Sentiment: Positive

Boston Scientific (BSX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Read More
image for news Boston Scientific Corporation (BSX) Is a Trending Stock: Facts to Know Before Betting on It
Penumbra, Inc. Reports Fourth Quarter and Full Year 2025 Financial Results
BSX, PEN
Published: February 25, 2026 by: PRNewsWire
Sentiment: Neutral

ALAMEDA, Calif., Feb. 25, 2026 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, today reported financial results for the fourth quarter and full year ended December 31, 2025.

Read More
image for news Penumbra, Inc. Reports Fourth Quarter and Full Year 2025 Financial Results
Ongoing Investigation into Boston Scientific Corporation (BSX): Contact Levi & Korsinsky About Potential Fraud
BSX
Published: February 23, 2026 by: Newsfile Corp
Sentiment: Neutral

New York, New York--(Newsfile Corp. - February 23, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Boston Scientific Corporation ("Boston Scientific Corporation") (NYSE:BSX) concerning potential violations of the federal securities laws. On February 4, 2026, Boston Scientific reported fourth-quarter 2025 results.

Read More
image for news Ongoing Investigation into Boston Scientific Corporation (BSX): Contact Levi & Korsinsky About Potential Fraud
Boston Scientific elects Cathy Smith and Christophe Weber to Board of Directors
BSX
Published: February 23, 2026 by: PRNewsWire
Sentiment: Neutral

MARLBOROUGH, Mass., Feb. 23, 2026 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) announced today the election of Cathy Smith and Christophe Weber to its Board of Directors, effective February 18, 2026.

Read More
image for news Boston Scientific elects Cathy Smith and Christophe Weber to Board of Directors
BSX vs. ABT: Which MedTech Stock is the Better Investment Now?
ABT, BSX
Published: February 20, 2026 by: Zacks Investment Research
Sentiment: Positive

Abbott edges out Boston Scientific in the MedTech faceoff, with valuation appeal, strong CGM momentum and strategic deals boosting its investment case.

Read More
image for news BSX vs. ABT: Which MedTech Stock is the Better Investment Now?
Back on the Radar: Prior Picks Offer Fresh Opportunity
BSX, NFLX
Published: February 18, 2026 by: Barrons
Sentiment: Positive

Sometimes the best new ideas are simply old winners ready for another run.

Read More
image for news Back on the Radar: Prior Picks Offer Fresh Opportunity
BSX Posts Q4 Earnings: Should You Buy, Sell or Hold the Stock?
BSX
Published: February 13, 2026 by: Zacks Investment Research
Sentiment: Positive

Boston Scientific BSX reported its fourth-quarter 2025 results on Feb. 4. Both top and bottom lines exceeded the company's guidance ranges and topped the respective Zacks Consensus Estimate.

Read More
image for news BSX Posts Q4 Earnings: Should You Buy, Sell or Hold the Stock?
Securities Fraud Investigation Into Boston Scientific Corporation (BSX) Announced – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm
BSX
Published: February 09, 2026 by: Business Wire
Sentiment: Neutral

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Boston Scientific Corporation (“Boston Scientific” or the “Company”) (NYSE: BSX) investors concerning the Company's possible violations of the federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON BOSTON SCIENTIFIC CORPORATION (BSX), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER Y.

Read More
image for news Securities Fraud Investigation Into Boston Scientific Corporation (BSX) Announced – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm
Reassessing The Boston Scientific Bull Thesis
BSX
Published: February 06, 2026 by: Forbes
Sentiment: Negative

On Wednesday, Boston Scientific (BSX) experienced a loss of nearly one-fifth of its market capitalization in a single trading session. The stock finished at $75.50, reaching a 52-week low, with a volume approximately six times greater than the 3-month average.

Read More
image for news Reassessing The Boston Scientific Bull Thesis
Securities Fraud Investigation Into Boston Scientific Corporation (BSX) Announced – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
BSX
Published: February 06, 2026 by: Business Wire
Sentiment: Neutral

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of Boston Scientific Corporation (“Boston Scientific” or the “Company”) (NYSE: BSX) on behalf of investors concerning the Company's possible violations of federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON BOSTON SCIENTIFIC CORPORATION (BSX), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING A CLAIM TO RECOVER YOUR LOSS. What Is The Investigation About? On February 4, 2026, Boston Scientific.

Read More
image for news Securities Fraud Investigation Into Boston Scientific Corporation (BSX) Announced – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
What Happened To Boston Scientific Stock?
BSX
Published: February 05, 2026 by: Forbes
Sentiment: Negative

Boston Scientific (BSX), a leading global player in medical devices, announced solid Q4 earnings but offered 2026 guidance that slightly fell short of elevated investor expectations. This response was marked by a drastic, high-volume liquidation event that quickly erased months of gains.

Read More
image for news What Happened To Boston Scientific Stock?
Investors in Boston Scientific Corporation (BSX) Warned of Potential Securities Fraud - Contact Levi & Korsinsky Today
BSX
Published: February 05, 2026 by: Newsfile Corp
Sentiment: Neutral

New York, New York--(Newsfile Corp. - February 5, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Boston Scientific Corporation ("Boston Scientific Corporation") (NYSE: BSX) concerning potential violations of the federal securities laws. On February 4, 2026, Boston Scientific reported fourth-quarter 2025 results.

Read More
image for news Investors in Boston Scientific Corporation (BSX) Warned of Potential Securities Fraud - Contact Levi & Korsinsky Today
Why Boston Scientific (BSX) is a Top Growth Stock for the Long-Term
BSX
Published: February 05, 2026 by: Zacks Investment Research
Sentiment: Positive

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Read More
image for news Why Boston Scientific (BSX) is a Top Growth Stock for the Long-Term
Boston Scientific Corporation (BSX) Q4 2025 Earnings Call Transcript
BSX
Published: February 04, 2026 by: Seeking Alpha
Sentiment: Neutral

Boston Scientific Corporation (BSX) Q4 2025 Earnings Call Transcript

Read More
image for news Boston Scientific Corporation (BSX) Q4 2025 Earnings Call Transcript
BSX Stock Dips in Premarket Trading Despite Q4 Earnings, Revenue Beat
BSX
Published: February 04, 2026 by: Zacks Investment Research
Sentiment: Neutral

BSX beats Q4 EPS and revenue estimates and lifts margins, but shares slide 9.1% in pre-market as investors weigh outlook and guidance.

Read More
image for news BSX Stock Dips in Premarket Trading Despite Q4 Earnings, Revenue Beat
Boston Scientific (BSX) Reports Q4 Earnings: What Key Metrics Have to Say
BSX
Published: February 04, 2026 by: Zacks Investment Research
Sentiment: Neutral

While the top- and bottom-line numbers for Boston Scientific (BSX) give a sense of how the business performed in the quarter ended December 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Read More
image for news Boston Scientific (BSX) Reports Q4 Earnings: What Key Metrics Have to Say
Boston Scientific Profit, Sales Rise but Issues Soft Guidance
BSX
Published: February 04, 2026 by: WSJ
Sentiment: Neutral

Sales rose 16%, but the medical-device maker issued a soft forecast for the year, sending shares down premarket.

Read More
image for news Boston Scientific Profit, Sales Rise but Issues Soft Guidance
4 Medical Product Stocks to Watch From a Challenging Industry (Revised)
BLFS, BSX, PAHC, RMD
Published: February 03, 2026 by: Zacks Investment Research
Sentiment: Negative

The Zacks Medical Products industry faces macro headwinds, keeping growth under pressure in 2026, but steady demand may continue. BSX, RMD, PAHC and BLFS reflect the favorable fundamentals.

Read More
image for news 4 Medical Product Stocks to Watch From a Challenging Industry (Revised)
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: RAPT Therapeutics, Inc. (Nasdaq – RAPT), Penumbra, Inc. (NYSE – PEN), Calavo Growers, Inc. (Nasdaq – CVGW), FONAR Corporation (Nasdaq - FONR)
BSX
Published: February 02, 2026 by: GlobeNewsWire
Sentiment: Neutral

BALA CYNWYD, Pa., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ([email protected]) or Marc Ackerman ([email protected]) at 855-576-4847. There is no cost or financial obligation to you.

Read More
image for news BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: RAPT Therapeutics, Inc. (Nasdaq – RAPT), Penumbra, Inc. (NYSE – PEN), Calavo Growers, Inc. (Nasdaq – CVGW), FONAR Corporation (Nasdaq - FONR)
4 Medical Product Stocks to Watch From a Challenging Industry
BLFS, BSX, PAHC, RMD
Published: February 02, 2026 by: Zacks Investment Research
Sentiment: Negative

The Zacks Medical products industry faces macro headwinds, keeping growth under pressure in 2026, but steady demand may continue. BSX, RMD, PAHC and BLFS reflect the favorable fundamentals.

Read More
image for news 4 Medical Product Stocks to Watch From a Challenging Industry
Boston Scientific (BSX) Q4 Earnings on the Horizon: Analysts' Insights on Key Performance Measures
BSX
Published: January 30, 2026 by: Zacks Investment Research
Sentiment: Positive

Beyond analysts' top-and-bottom-line estimates for Boston Scientific (BSX), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended December 2025.

Read More
image for news Boston Scientific (BSX) Q4 Earnings on the Horizon: Analysts' Insights on Key Performance Measures
Artisan Global Opportunities Fund Q4 2025 Portfolio Update
ARGX, BAESY, BKR, BSX, COF, COIN, INSM, LEG, LHX, LRCX, LRLCY, NFLX, ORCL, PYPL, RTX, SBUX, SGI, SNOW, TCEHY, ZTS
Published: January 29, 2026 by: Seeking Alpha
Sentiment: Neutral

Among our top contributors in Q4 were Argenx, Lam Research and Insmed. Among our biggest detractors in Q4 were Oracle, Netflix and BAE Systems. During the quarter, we initiated new positions in RTX (Raytheon), Capital One and Somnigroup. In addition to Insmed and BAE, we also added to L3Harris, a global aerospace and defense company.

Read More
image for news Artisan Global Opportunities Fund Q4 2025 Portfolio Update

About Boston Scientific Corporation (BSX)

  • IPO Date 1992-05-19
  • Website https://www.bostonscientific.com
  • Industry Medical - Devices
  • CEO Michael F. Mahoney
  • Employees 53000

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, and atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, cryotherapy ablation systems, and micro and drainage catheters to treat cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.